摘要: Abstract Objectives: Growth signaling is instrumental in tumor development. Insight into pathways by molecular and cellular biology has changed the development of new anticancer agents. Outside field urology specifically targeted drugs such as imatinib mesylate gefitinib showed impressive activity chronic myeloid leukemia non-small cell lung cancer, respectively. Methods: Literature search PubMed documented publications abstracts from meetings. Results: Preclinical data prostate cancer shows upregulation a wide variety growth factors their receptors PDGF, EGF, IGF, FGF, VEGF suggesting efficacy agents targeting these pathways. Here preclinical evidence first clinical on use signal reviewed. Although some transduction inhibition monotherapy was reported, combination with chemotherapy radiotherapy seemed most promising cancer. Conclusion: So-called smart are small molecules at specific These will dominate trials years to come either single-drug modality, but more likely treatment.
elsevier.com
sci-hub.se 参考文章(174)
William D. Figg, Erwin A. Kruger, Douglas K. Price, Sonia Kim, William D. Dahut, Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Investigational New Drugs. ,vol. 20, pp. 183- 194 ,(2002) , 10.1023/A:1015626410273
Matthew R. Smith, Philip W. Kantoff, Peroxisome Proliferator-Activated Receptor Gamma (PPARγ as a Novel Target for Prostate Cancer Investigational New Drugs. ,vol. 20, pp. 195- 200 ,(2002) , 10.1023/A:1015670126203
Carlo Vicentini, Claudio Festuccia, Giovanni Luca Gravina, Adriano Angelucci, Angelo Marronaro, Mauro Bologna, Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures Journal of Cancer Research and Clinical Oncology. ,vol. 129, pp. 165- 174 ,(2003) , 10.1007/S00432-003-0420-3
Antonio Di Cristofano, Marika De Acetis, Andrew Koff, Carlos Cordon-Cardo, Pier P Pandolfi, Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nature Genetics. ,vol. 27, pp. 222- 224 ,(2001) , 10.1038/84879
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
Stephanie J. McAlhany, Jennifer A. Tuxhorn, Truong D. Dang, David R. Rowley, Feng Yang, Inhibition of Transforming Growth Factor-β Activity Decreases Angiogenesis in a Human Prostate Cancer-reactive Stroma Xenograft Model Cancer Research. ,vol. 62, pp. 6021- 6025 ,(2002)
Jürgen Dunst, Steffi Pigorsch, Gabriele Hänsgen, Ingrid Hintner, Christine Lautenschläger, Axel Becker, Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients : Does anemia stimulate angiogenesis? Strahlentherapie Und Onkologie. ,vol. 175, pp. 93- 96 ,(1999) , 10.1007/BF02742340
Carlos Cordon-Cardo, David Verbel, Marija Drobnjak, Howard I. Scher, Iman Osman, Michael Morris, David Agus, Jeffrey S. Ross, HER-2/neu (p185neu) Protein Expression in the Natural or Treated History of Prostate Cancer Clinical Cancer Research. ,vol. 7, pp. 2643- 2647 ,(2001)
Daniel Gioeli, Robert A Sikes, Michael J Weber, Eric A Bissonette, Robert E Bakin, Constitutive Activation of the Ras/Mitogen-activated Protein Kinase Signaling Pathway Promotes Androgen Hypersensitivity in LNCaP Prostate Cancer Cells Cancer Research. ,vol. 63, pp. 1981- 1989 ,(2003)
Noah Craft, Yuriy Shostak, Michael Carey, Charles L. Sawyers, A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine. ,vol. 5, pp. 280- 285 ,(1999) , 10.1038/6495